Antimicrobial effects of inhaled sphingosine against Pseudomonas aeruginosa in isolated ventilated and perfused pig lungs.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
02
2022
accepted:
04
07
2022
entrez:
21
7
2022
pubmed:
22
7
2022
medline:
26
7
2022
Statut:
epublish
Résumé
Ex-vivo lung perfusion (EVLP) is a save way to verify performance of donor lungs prior to implantation. A major problem of lung transplantation is a donor-to-recipient-transmission of bacterial cultures. Thus, a broadspectrum anti-infective treatment with sphingosine in EVLP might be a novel way to prevent such infections. Sphingosine inhalation might provide a reliable anti-infective treatment option in EVLP. Here, antimicrobial potency of inhalative sphingosine in an infection EVLP model was tested. A 3-hour EVLP run using pig lungs was performed. Bacterial infection was initiated 1-hour before sphingosine inhalation. Biopsies were obtained 60 and 120 min after infection with Pseudomonas aeruginosa. Aliquots of broncho-alveolar lavage (BAL) before and after inhalation of sphingosine were plated and counted, tissue samples were fixed in paraformaldehyde, embedded in paraffin and sectioned. Immunostainings were performed. Sphingosine inhalation in the setting of EVLP rapidly resulted in a 6-fold decrease of P. aeruginosa CFU in the lung (p = 0.016). We did not observe any negative side effects of sphingosine. Inhalation of sphingosine induced a significant decrease of Pseudomonas aeruginosa at the epithelial layer of tracheal and bronchial cells. The inhalation has no local side effects in ex-vivo perfused and ventilated pig lungs.
Sections du résumé
BACKGROUND
Ex-vivo lung perfusion (EVLP) is a save way to verify performance of donor lungs prior to implantation. A major problem of lung transplantation is a donor-to-recipient-transmission of bacterial cultures. Thus, a broadspectrum anti-infective treatment with sphingosine in EVLP might be a novel way to prevent such infections. Sphingosine inhalation might provide a reliable anti-infective treatment option in EVLP. Here, antimicrobial potency of inhalative sphingosine in an infection EVLP model was tested.
METHODS
A 3-hour EVLP run using pig lungs was performed. Bacterial infection was initiated 1-hour before sphingosine inhalation. Biopsies were obtained 60 and 120 min after infection with Pseudomonas aeruginosa. Aliquots of broncho-alveolar lavage (BAL) before and after inhalation of sphingosine were plated and counted, tissue samples were fixed in paraformaldehyde, embedded in paraffin and sectioned. Immunostainings were performed.
RESULTS
Sphingosine inhalation in the setting of EVLP rapidly resulted in a 6-fold decrease of P. aeruginosa CFU in the lung (p = 0.016). We did not observe any negative side effects of sphingosine.
CONCLUSION
Inhalation of sphingosine induced a significant decrease of Pseudomonas aeruginosa at the epithelial layer of tracheal and bronchial cells. The inhalation has no local side effects in ex-vivo perfused and ventilated pig lungs.
Identifiants
pubmed: 35862397
doi: 10.1371/journal.pone.0271620
pii: PONE-D-22-06001
pmc: PMC9302828
doi:
Substances chimiques
Anti-Infective Agents
0
Sphingosine
NGZ37HRE42
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0271620Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Microb Drug Resist. 2016 Jul;22(5):412-31
pubmed: 26866778
Nat Rev Mol Cell Biol. 2008 Feb;9(2):139-50
pubmed: 18216770
Rev Mal Respir. 2020 Sep;37(7):561-571
pubmed: 32684338
Am J Transl Res. 2020 Jan 15;12(1):153-161
pubmed: 32051744
Surg Infect (Larchmt). 2018 Nov/Dec;19(8):792-803
pubmed: 30277846
J Lipid Res. 2020 Jun;61(6):896-910
pubmed: 32156719
EMBO Mol Med. 2014 Aug 01;6(9):1205-14
pubmed: 25085879
Curr Opin Pulm Med. 2009 Mar;15(2):138-42
pubmed: 19532029
Curr Top Microbiol Immunol. 2016;398:3-33
pubmed: 27406189
J Mol Med (Berl). 2020 Feb;98(2):209-219
pubmed: 31863153
PLoS One. 2018 Mar 5;13(3):e0193168
pubmed: 29505574
Adv Drug Deliv Rev. 2018 Aug;133:66-75
pubmed: 29698625
Transplant Proc. 2011 May;43(4):1290-1
pubmed: 21620113
Curr Opin Pulm Med. 2017 Nov;23(6):574-579
pubmed: 28858970
J Mol Med (Berl). 2019 Aug;97(8):1195-1211
pubmed: 31222488
J Heart Lung Transplant. 2006 Jan;25(1):99-105
pubmed: 16399537
Lancet Respir Med. 2014 Jan;2(1):73-82
pubmed: 24461904
Cell Host Microbe. 2017 Jun 14;21(6):707-718.e8
pubmed: 28552668
Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416
pubmed: 15699079
Eur J Cardiothorac Surg. 2003 Oct;24(4):601-7
pubmed: 14500081
J Surg Res. 2017 Nov;219:354-359
pubmed: 29078905
Sci Rep. 2021 Sep 20;11(1):18607
pubmed: 34545108
Cochrane Database Syst Rev. 2013 Jun 06;(6):CD009098
pubmed: 23740697
J Heart Lung Transplant. 2020 Oct;39(10):1016-1027
pubmed: 32782073
Cell Physiol Biochem. 2019;53(6):1015-1028
pubmed: 31854953
J Biol Chem. 2021 Jan-Jun;296:100650
pubmed: 33839155
Am J Respir Cell Mol Biol. 2010 Jun;42(6):716-24
pubmed: 19635928
J Heart Lung Transplant. 2016 Oct;35(10):1158-1169
pubmed: 27772668
mBio. 2019 Dec 3;10(6):
pubmed: 31796543
Cell Physiol Biochem. 2016;38(6):2094-102
pubmed: 27184795
Mol Psychiatry. 2018 Dec;23(12):2324-2346
pubmed: 30038230
Intensive Care Med. 2003 Nov;29(11):1981-8
pubmed: 13680109
J Biol Chem. 2020 May 29;295(22):7686-7696
pubmed: 32327486
Am J Respir Crit Care Med. 2020 Oct 15;202(8):1133-1145
pubmed: 32569477
J Thorac Cardiovasc Surg. 2017 Jan;153(1):197-204
pubmed: 27742245
Med Sci Monit Basic Res. 2015 Feb 03;21:9-14
pubmed: 25644463
Front Cell Infect Microbiol. 2020 May 12;10:215
pubmed: 32477967
Comput Struct Biotechnol J. 2020 Sep 15;18:2547-2555
pubmed: 33033577
Transl Res. 2017 Jan;179:84-96
pubmed: 27559681
Cell Physiol Biochem. 2017;43(4):1603-1616
pubmed: 29040968